Fig. 6

Up-regulation of SGLT1 and SGLT2 at an arterial site at high risk (aortic arch) and following stimulation of an arterial site at low risk (thoracic aorta) with either Ang II or an eNOS inhibitor. The segments of thoracic aorta are incubated either with VAS (1 µM), LOS (1 µM), SOTA (100 nM) or EMPA (100 nM) for 30 min before the addition of (a-e, l) Ang II (100 nM) or (f–j, m) N^ω-nitro-L-arginine (L-NA, 300 µM) for 15 h, and the subsequent determination of (a–J) the expression level of target proteins by Western blot analysis, and (k–m) dihydroethidium staining by confocal microscope. Results are shown as representative immunoblots and micrography of dihydroethidium staining (upper and left panels) and corresponding cumulative data (lower and right panels). Data are expressed as mean ± SEM of n = 3–4. ^*P < 0.05 vs. control thoracic aorta (a–j, l, m) and outer aortic arch (k), and ^#P < 0.05 vs. Ang II-treated thoracic aorta (a–e, l) and L-NA-treated thoracic aorta (f–j, m)